Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 14/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6078746 | 0.92 | SIGMAR1 (0.59) | CCR3SIGMAR1MCHR1 | |
| SCHEMBL6079692 | 0.92 | SIGMAR1 (0.59) | CCR3SIGMAR1MCHR1 | |
| SCHEMBL6078750 | 0.92 | SIGMAR1 (0.59) | CCR3SIGMAR1MCHR1 | |
| SCHEMBL6080389 | 0.90 | MCHR1 (0.54) | CCR3SIGMAR1MCHR1 | |
| SCHEMBL6079258 | 0.89 | DRD2 (0.54) | CCR3SIGMAR1 | |
| SCHEMBL6080004 | 0.86 | SIGMAR1 (0.53) | CCR3SIGMAR1 | |
| SCHEMBL6078429 | 0.86 | SIGMAR1 (0.52) | CCR3SIGMAR1 | |
| SCHEMBL6080158 | 0.85 | CXCR3 (0.54) | SIGMAR1 | |
| SCHEMBL6080285 | 0.83 | CCR3 (0.47) | CCR3SIGMAR1 | |
| SCHEMBL6080281 | 0.83 | CCR3 (0.47) | CCR3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060094716-A1 | 1-Pyridin-4-yl-urea derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2006-05-04 | — | — | US | claimed |
| EP-1554249-A2 | 1-PYRIDIN-4-YL-UREA DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2005-07-20 | — | — | EP | claimed |
| WO-2004026836-A2 | 1-PYRIDIN-4-YL-UREA DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-04-01 | — | — | WO | claimed |
| US-20060094716-A1 | 1-Pyridin-4-yl-urea derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2006-05-04 | — | — | US | disclosed |
| EP-1554249-A2 | 1-PYRIDIN-4-YL-UREA DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004026836-A2 | 1-PYRIDIN-4-YL-UREA DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094716-A1 | 1-Pyridin-4-yl-urea derivatives | P2RY4, P2RX4, REN | CCR3 3917/4885SIGMAR1 162/4885MCHR1 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.